Margret B. Einarson, Ph.D., Manager, High Throughput Screening Facility, Fox Chase Cancer Center

项目摘要 我是NCI指定的综合医院的高通量筛选设施（HTSF）的经理。 Fox Chase Cancer Center（英语：Fox Chase Cancer Center）HTSF提供筛选平台和专门的 用于增加实验吞吐量的仪器。特别是，HTSF允许调查人员利用 RNAi和化合物文库，以及用这些文库进行大规模筛选所需的专门仪器。 资源自HTSF成立以来，我一直是HTSF的经理，并指导了HTSF的建立和发展。 维护设施的各个方面。我设法收购了一套高温超导设备和库， 建立了所有的标准操作规程（SOP），并创建了一个工作管道， 发展到为调查人员统计打击对象。在我的领导下成立HTSF后， 2010年，NCI首次对其进行审查，作为癌症中心的新增设施 支持补助金（CCSG），它被评为“优秀”。总的来说，我为之创造的资源的活力 2007年至2010年期间使用HTSF的44篇出版物证明了分子筛选的有效性。 2015.在最近的CCSG审查期间（2011-2014年）， CCSG第一次审查期间的出版物数量。在这段时间里，平均有超过 每年为1000个人预订设备使用。这些数据表明， 已经建立并将继续发展的技术是气候变化框架公约各实验室的一项强大和关键的科学资产。 随着技术和研究方向的发展，我调查了教师，以确定新的技术平台 为HTSF，我领导了两个S10共享仪器的准备工作， 应用程序，允许购买Guava EasyCyte台式流式细胞仪和Luminex 100/200，多路复用 生物标志物分析仪收购这一新技术平台将补充现有资源， 筛查人员，但至关重要的是允许HTSF利用患者样本和动物模型为研究人员服务。我 支持和实施HTSF中提供的技术，对于他们继续 卓越和可用性。

Project Summary I am the Manager of the High Throughput Screening Facility (HTSF) at the NCI-designated comprehensive cancer center Fox Chase Cancer Center (FCCC). The HTSF provides screening platforms and specialized instrumentation for increased experimental throughput. In particular, the HTSF allows investigators to utilize RNAi and compound libraries, and the specialized instrumentation required for large scale screening with these resources. I have been the Manager of the HTSF since its inception, and have guided the establishment and maintenance of every aspect of the facility. I managed the acquisition of a suite of HTS equipment and libraries, established all the standard operating procedures (SOPs) and created a working pipeline from assay development to statistical hit-picking for investigators. After the establishment of the HTSF under my management, on its first review by the NCI in 2010 as a proposed facility for addition to the Cancer Center Support Grant (CCSG), it was rated as “Outstanding.” Overall, the vitality of the resource I have created for molecular screening is evidenced by forty-four publications that have utilized the HTSF between the years 2007- 2015. Within the most recent CCSG review period (2011-2014), there was a three-fold increase in the total number of publications over the first CCSG review period. During this time period, there was an average of over one thousand individual reservations for equipment use per annum. These data indicate that the resources I have established and continue to develop are robust and a pivotal scientific asset for the laboratories at FCCC. As technologies and research directions evolve, I have surveyed the faculty to identify new technology platforms for the HTSF, and I have led the preparation of two S10 shared instrumentation grants two successful S10 applications allowing the purchase of the Guava EasyCyte benchtop FACS, and a Luminex 100/200, multiplexing biomarker analyzer. The acquisition of this new technology platform will complement the resources available to screeners, but crucially allow the HTSF to serve investigators utilizing patient samples and animal models. My efforts supporting and implementing the technologies provided in the HTSF is crucial to their continued excellence and availability.